Wegovy (Semaglutide 2.4mg)
The higher-dose formulation of semaglutide, specifically approved for chronic weight management. Launched in India in June 2025, delivering 15–17% average weight loss in clinical trials — and now with cardiovascular event reduction data even without diabetes.
Wegovy (semaglutide 2.4mg) launched in India in June 2025 at ₹10,850–₹16,400/month. Indian generic equivalents are available from March 2026 at ₹2,500–₹4,000/month.
What Is Wegovy?
Wegovy is Novo Nordisk's once-weekly semaglutide injection at a maximum dose of 2.4mg/week — the highest approved dose of semaglutide. Unlike Ozempic (which is approved for type 2 diabetes), Wegovy is approved specifically for chronic weight management in adults with:
- BMI ≥30 (obesity), or
- BMI ≥27 (overweight) with at least one weight-related comorbidity such as hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea
Wegovy and Ozempic contain the identical semaglutide molecule. The difference is purely in the approved dose ceiling (2.4mg vs 1mg) and the approved indication (weight management vs diabetes). This distinction matters for insurance coverage and physician prescribing patterns, though clinically the molecule behaves identically at equivalent doses.
The STEP Trials — What the Evidence Shows
The pivotal clinical trials for Wegovy are the STEP (Semaglutide Treatment Effect in People with obesity) trials. Key results:
| Trial | Population | Duration | Weight Loss | Key Finding |
|---|---|---|---|---|
| STEP-1 | Adults with obesity, no T2D | 68 weeks | 14.9% | 1/3 of participants lost >20% body weight |
| STEP-2 | Adults with T2D and obesity | 68 weeks | 9.6% | Greater HbA1c reduction vs placebo |
| STEP-3 | Obesity + intensive behavioral therapy | 68 weeks | 16% | Behavior therapy + drug superior to drug alone |
| STEP-4 | Weight loss maintenance | 48-week continuation | +7% vs placebo | Discontinuation leads to weight regain |
The STEP-1 trial (PubMed, 2021) is the landmark study — 1961 adults with obesity, semaglutide 2.4mg vs placebo over 68 weeks. Average weight loss was 14.9% with semaglutide versus 2.4% with placebo. The 32% of participants who lost more than 20% of body weight is particularly notable.
How Wegovy Differs from Ozempic
The core distinction: dose and indication.
- Ozempic maxes at 1mg/week, Wegovy maxes at 2.4mg/week
- Higher dose = greater appetite suppression and more weight loss
- Wegovy requires longer titration (17 weeks to reach full dose vs 8–12 for Ozempic)
- Side effects are similar but GI symptoms can be slightly more pronounced at 2.4mg
- Wegovy is priced higher due to the additional doses in the pen
Wegovy vs Mounjaro (Tirzepatide) — The Honest Comparison
Wegovy achieves 15–17% weight loss. Mounjaro (tirzepatide) achieves 21–22%. Mounjaro's superiority comes from its dual GLP-1 + GIP mechanism — adding GIP receptor activation provides fat cell insulin sensitization on top of GLP-1 appetite suppression. Head-to-head trial data (SURMOUNT-5, 2024) confirmed tirzepatide's advantage.
| Feature | Wegovy (Semaglutide 2.4mg) | Mounjaro (Tirzepatide 15mg) |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | GLP-1 + GIP dual agonist |
| Average weight loss | 15–17% | 21–22% |
| Achieving ≥20% loss | ~32% | ~56% |
| India branded price/month | ₹10,850–₹16,400 | ₹13,125–₹25,781 |
| India generic available | Yes (from March 2026) | Limited (2026–2027) |
| Cardiovascular trial data | SELECT trial (20% MACE reduction) | SURPASS-CVOT (pending full data) |
SELECT Trial — Cardiovascular Benefits Without Diabetes
The SELECT trial (2023) was a landmark study enrolling over 17,000 adults with obesity or overweight and established cardiovascular disease — but without diabetes. Semaglutide 2.4mg reduced the composite endpoint of cardiovascular death, non-fatal MI, and non-fatal stroke by 20% over 3.3 years of follow-up.
This was significant because it demonstrated that semaglutide's cardiovascular benefit extends beyond glucose lowering — likely through direct vascular anti-inflammatory effects and weight-loss-mediated improvements in blood pressure, lipids, and endothelial function.
68-Week Titration Protocol
- Weeks 1–4: 0.25mg/week
- Weeks 5–8: 0.5mg/week
- Weeks 9–12: 1.0mg/week
- Weeks 13–16: 1.7mg/week
- Week 17+: 2.4mg/week (maintenance dose)
If side effects at any step are intolerable, delay dose escalation by 4 additional weeks at the current dose. Slow titration is the single most effective strategy for minimizing nausea.
Muscle Preservation on Wegovy
As with all GLP-1 drugs, muscle loss is the underappreciated metabolic cost of semaglutide-induced weight loss. Studies show 25–40% of weight lost is lean mass without intentional countermeasures. For longevity-focused patients in India, this matters enormously — muscle mass is the single best predictor of metabolic health, fall prevention, and insulin sensitivity in middle and older age.
Creatine monohydrate 3–5g/day (the most evidence-backed supplement for lean mass during caloric restriction) · Protein 1.2g/kg body weight minimum (eggs, paneer, sattu, whey) · Resistance training 2–3x/week · Vitamin D if below 50 ng/mL (critical for muscle protein synthesis)
Supplements for Wegovy Users in India
- Creatine monohydrate: 3–5g daily. Best-evidenced supplement for preserving lean mass. No loading phase needed. Widely available in India at ₹500–₹1,500/month.
- Methylcobalamin B12: 1000mcg sublingual weekly. Reduced food intake over months depletes B12 stores. Sublingual absorption bypasses gut issues.
- Magnesium glycinate: 300–400mg before bed. Reduced caloric intake commonly depletes magnesium, worsening sleep and muscle function.
- Vitamin D: 2,000–4,000 IU if below 50 ng/mL. Most Indians are already deficient; Wegovy-related reduced intake can worsen this.
Biomarker Monitoring Every 3 Months
- Body weight and waist circumference
- HbA1c (if pre-diabetic or diabetic)
- Fasting glucose and fasting insulin
- Lipid panel + ApoB
- ALT/AST (liver enzymes — often improve with weight loss)
- B12 annually; ferritin every 6 months
- Blood pressure and resting heart rate
Frequently Asked Questions
What is Wegovy and how does it differ from Ozempic?
Wegovy and Ozempic both contain semaglutide. Wegovy uses a higher maximum dose (2.4mg/week) and is approved for weight management, while Ozempic (1mg/week max) is approved for type 2 diabetes. The higher Wegovy dose produces greater weight loss — 15–17% versus 5–12% with Ozempic doses.
Wegovy vs Mounjaro India — which is better for weight loss?
Mounjaro (tirzepatide) produces greater weight loss — 21–22% versus Wegovy's 15–17% — due to its dual GLP-1 + GIP mechanism. However, Wegovy has stronger long-term cardiovascular safety data (SELECT trial) and is now available as a generic in India. The best choice depends on your metabolic profile and budget.
How long does it take Wegovy to work?
Appetite reduction is typically noticeable within 1–2 weeks. Meaningful weight loss (1–2%) appears by weeks 4–8. Full efficacy at the 2.4mg dose is reached at week 17. Weight loss continues for 52–60 weeks before plateauing. Most of the total achievable loss occurs in the first 40 weeks.
What supplements should I take while on Wegovy in India?
Critical supplements: creatine monohydrate (3–5g/day), methylcobalamin B12 (1000mcg weekly), magnesium glycinate (300–400mg nightly), and vitamin D if deficient. Prioritize protein intake at 1.2–1.6g/kg body weight daily. Good Indian sources: eggs, paneer, dal, sattu, and whey protein.